SecBot SecBot
PRESS-RELEASE ·Filed Aug 14, 2026

NMAD

NOMAD Power Solutions, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor Q3 2026 results for first consolidated financials including NOMAD Transportable Power Systems. The transformation is early-stage; commercial traction (DSO sale) and Voyager 3G adoption will be key catalysts. Stock has been highly volatile post-transformation announcement.

DirectionNeutral
Confidencemedium
Horizonweeks
Latest settled — T+20d
NMAD ▼ -19.26% at T+20d
NEUTRAL call -19.26% · α vs SPY -17.27% · entry $4.05 → $3.27
Next anchor: T+60d in 13d
Latest observation: T+49 -6.10% FF3 residual α
Entry = T+0 close
Aug 14, 2026
via day close
T+1d
-3.70%
call -3.70% · α -3.23%
$3.90
settled 2mo ago
T+5d
+6.17%
call +6.17% · α +7.54%
$4.30
settled 2mo ago
T+20d
-19.26%
call -19.26% · α -17.27%
$3.27
settled 6w ago
T+60d
Pending
in 13d

Price Chart

Loading chart...

Executive Summary

NOMAD Power Solutions (formerly LIXTE Biotechnology) filed its Q2 2026 10-Q and provided a business update. The filing reflects legacy biotech operations only, as the acquisition of NOMAD Transportable Power Systems closed after quarter-end. No current-period financial results were disclosed, making this a non-financial update focused on corporate transformation and operational milestones.

Key Facts

  • Corporate name change to NOMAD Power Solutions completed post-Q2; new Nasdaq symbol NMAD.
  • Acquisition of NOMAD Transportable Power Systems closed after June 30, 2026; Q2 10-Q reflects legacy LIXTE only.
  • Stuart D. Porter (Denham Capital) appointed to board; Denham has overseen $12B+ in energy investments.
  • Operating subsidiary sold two commercial BESS units to Kansas utility DSO Electric Cooperative.
  • Third-generation Voyager platform launched with 50%+ energy capacity increase.
  • Included in Russell Microcap Index in June; options trading began on Cboe in July.
  • Company exploring strategic alternatives for legacy clinical-stage pharmaceutical/med-tech operations.

Financial Impact

No current-period financials disclosed; legacy biotech operations have minimal revenue (previously near-zero).

Risk Factors

  • No revenue from new energy business yet reported; execution risk on scaling deployments.
  • Legacy biotech operations may require divestiture or wind-down costs.

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345335
5 reports for NMAD
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NMAD — sortable, filterable
TypeNow
Oct 6, 2026
20d ago
8-K
NEUTRAL ★ 2/10
$4.35 $4.28▼ −1.61%▼ −1.47%$4.04 (−7.13%)
Sep 30, 2026
26d ago
8-K
BEARISH ★ 6/10
$3.86 $4.27▼ −10.62%▼ −9.32%$4.04 (−4.66%)
Aug 14, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$4.05 $4.30▲ +6.17%▲ +7.54%$4.04 (−0.25%)
Jul 31, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$4.48 $3.60▼ −19.64%▼ −23.15%$4.04 (−9.82%)
Jul 10, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$6.26 $5.39▼ −13.83%▼ −13.27%$4.04 (−35.41%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026